At 4.0% CAGR, the APAC Epirubicin Market is projected to be worth US$ 37,447.28 thousand by 2028, says Business Market Insights           

According to Business Market Insights’ research, the APAC epirubicin market was valued at US$ 29,679.40 thousand in 2022 and is expected to reach US$ 37,447.28 thousand by 2028, registering an annual growth rate of 4.0% from 2022 to 2028. Increasing awareness regarding cancer and rising prevalence of cancer are the critical factors attributed to the market expansion.          

Cancer is the second leading cause of mortality across the region. Furthermore, National Cancer Institute (NCI) funded researchers working at the National Institute of Health (NIH) campus across the region are seeking ways to address breast cancer more effectively. Some research is fundamental, exploring questions as diverse as the biological foundations of cancer and the social factors that affect cancer risk. Several research efforts have taken place in recent years by NCI. For instance, the Breast Specialized Programs of Research Excellence (Breast SPOREs) are designed to move basic scientific findings into clinical settings quickly. The Breast SPOREs support the development of new therapies, technologies, and studies for a better understanding of tumor resistance, diagnosis, prognosis, screening, prevention, and treatment of breast cancer. Secondly, the NCI Cancer Intervention and Surveillance Modeling Network (CISNET) focuses using modeling to improve knowledge to prevent, early detection, screening, and treatment affect breast cancer results. Ongoing programs at NCI help prevention and early detection research in different cancers. The factors mentioned above would fuel the growth of the epirubicin market across the region.    

On the contrary, elevated risk of adverse effects due to epirubicin hurdles the growth of APAC epirubicin market.    

• Based on dosage, the APAC epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held 38.7% market share in 2022, amassing US$ 11,488.46 thousand. It is projected to garner US$ 14,700.85 thousand by 2028 to expand at 4.2% CAGR during 2022–2028.    
• Based on application, the APAC epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held 72.2% market share in 2022, amassing US$ 21,414.09 thousand. It is projected to garner US$ 27,214.15 thousand by 2028 to expand at 4.1% CAGR during 2022–2028.     
• Based on distribution channel, the APAC epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 62.4% market share in 2022, amassing US$ 18,522.00 thousand. It is projected to garner US$ 23,923.37 thousand by 2028 to expand at 4.4% CAGR during 2022–2028.          
• Based on country, the APAC epirubicin market has been categorized into China, India, Japan, South Korea, Australia, and rest of APAC.  Our regional analysis states that China captured 38.2% market share in 2022. It was assessed at US$ 11,323.92 thousand in 2022 and is likely to hit US$ 14,639.08 thousand by 2028, exhibiting a CAGR of 4.4% during the forecast period.            

Key players dominating the APAC epirubicin market are Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Miracalus Pharma Pvt. Ltd., Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. among others.   

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com